GSK

Noetik says it met the first milestone of its five-year licensing agreement with GSK (announced January 2026, $50 million upfront capital and near-term milestones) and that GSK teams are using its OCTO-VC models for virtual cell experiments, patient stratification and H&E data enrichment.

Partners: Noetik

Relation announced a strategic research collaboration with GSK to generate large-scale human cellular perturbation data and deploy it into models including MORGAN, its cellular biology foundation model; Relation reports up to $110 million in upfront and success-based milestone payments.

Partners: Relation

GSK and the Fleming Initiative announced six Grand Challenges, funded from GSK's GBP 45 million pledge, that use technologies including advanced AI. One programme will build an AI/ML model to design antibiotics for multi-drug-resistant Gram-negative bacteria, and another will build AI models that predict how drug-resistant pathogens emerge and spread.

Partners: Fleming Initiative

City A.M. reports that GSK's director of AI and machine learning told London Tech Week that agentic AI is already affecting every asset in the R&D pipeline and is a live operational tool.

The same City A.M. report says GSK is using generative AI to scan internal and external datasets, including literature, bench results and clinical trials, to try to match a treatment to an individual patient.

Vendor case study: Weights & Biases says GSK and Microsoft collaborated on AIGA, an internal framework for generative AI and agentic solutions.

Partners: Microsoft, Weights & Biases

Vendor case study: Weights & Biases says GSK built manufacturing digital twins at three levels of sophistication, with real-time sensors feeding ML workflows that predict batch trajectories, and that GSK has optimized 13 key products this way.

Partners: Weights & Biases

Weights & Biases says GSK replaced a two-person check of environmental petri dishes with a one-person-plus-AI deep-learning system, operating across nine manufacturing sites and about 3 million images a year.

Partners: Weights & Biases

GSK announced a new $1.2 billion US investment in advanced manufacturing facilities and AI and advanced digital technologies, including new AI and digital capabilities across its five existing US manufacturing sites.

Weights & Biases says GSK now uses agents that detect anomalies, present root-cause hypotheses to the brand manager and simulate downstream scenarios, in an agentic supply-chain setup built with Microsoft.

Partners: Microsoft, Weights & Biases

GSK says it will work with Tempus, using Tempus's AI/ML capability and de-identified patient data, to improve clinical trial design, speed up enrolment and identify drug targets. GSK made a $70 million initial payment.

Partners: Tempus